Atlas Trials

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Clinical trial NCT05139095 · RECRUITING

Trial details

NCT number
NCT05139095
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Gestational Trophoblastic Neoplasia
Start date
2022-01-27
Primary completion
2026-12-01
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.